Status:
COMPLETED
Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis
Lead Sponsor:
ALK-Abelló A/S
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18-55 years
Phase:
PHASE3
Brief Summary
This trial is performed to assess the efficacy and safety of ALK-depot SQ mites for treatment of atopic dermatitis
Eligibility Criteria
Inclusion
- Positive specific IgE to house dust mites
- Atopic dermatitis according to Hanifin/Rajka
- Chronic course of Atopic dermatitis
- SCORAD larger than 25 points
Exclusion
- Erythrodermia
- Syst.treatment with gcs or immunosuppressive agents in the prev.4 weeks
- History of specific immunotherapy with mites
- UV radiation
- Group 4 topical corticosteroids (European classification)
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT00310492
Start Date
April 1 2006
End Date
November 1 2009
Last Update
December 29 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Hochschule Hannover, Klinik für Dermatologie und Venerologie
Hanover, Germany, D-30449 Hannover